fullerene c60 has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolshakova, O; Golomidov, I; Komissarov, A; Latypova, E; Sarantseva, S; Sharoyko, V; Slepneva, Е; Slobodina, A; Tennikova, T; Zherebyateva, O | 1 |
| Cai, X; Feng, Z; Hou, B; Jia, H; Li, W; Liu, J; Liu, Z; Luo, C | 1 |
2 other study(ies) available for fullerene c60 and Parkinson Disease
| Article | Year |
|---|---|
The neuroprotective effect of fullerenols on a model of Parkinson's disease in Drosophila melanogaster.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Fullerenes; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2020 |
Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Cell Death; Cell Line, Tumor; Cell Survival; DNA Damage; Electron Transport Chain Complex Proteins; Free Radical Scavengers; Fullerenes; Herbicides; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Diseases; Models, Biological; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species | 2008 |